Affinage

Showing ZBTB7A — FBI-1 is a alias.

ZBTB7A

Zinc finger and BTB domain-containing protein 7A · UniProt O95365

Length
584 aa
Mass
61.4 kDa
Annotated
2026-06-11
100 papers in source corpus 48 papers cited in narrative 47 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ZBTB7A (FBI-1/LRF/Pokemon) is a sequence-specific BTB-zinc finger transcription factor that controls cell proliferation, differentiation, metabolism, and lineage-specific gene programs, acting predominantly as a transcriptional repressor while also functioning as a genome-wide chromatin accessibility transducer (PMID:15662416, PMID:25184678, PMID:29813070). It is built from an N-terminal POZ/BTB domain that mediates homodimerization and a C-terminal array of four Krüppel-type zinc fingers that confer specific binding to GC-rich elements with flexible orientation and spacing (PMID:9973611, PMID:12750370). Through its POZ domain it recruits corepressor–HDAC machinery (Sin3A/HDAC1, NCoR, SMRT, BCoR) to silence target promoters, drive histone H3/H4 deacetylation, and—via MBD3-dependent recruitment of the Mi-2/NuRD complex linked to DNMTs and HP1—impose DNA-methylation-based silencing (PMID:18801742, PMID:18368381, PMID:19244234, PMID:23658227). The same POZ surface also directly competes with or sequesters other DNA-binding factors, including Sp1 at GC boxes, p53 at responsive elements, and SOX9, redirecting promoter occupancy (PMID:12004059, PMID:19244234, PMID:23727861). Through this repertoire ZBTB7A represses cell-cycle and tumor-suppressor genes including ARF, Rb, and p21/CDKN1A, positioning it as a controller of the ARF–p53–p21 axis whose overexpression transforms cells and whose loss bypasses senescence (PMID:15662416, PMID:18801742, PMID:19244234, PMID:23727861). ZBTB7A is a master repressor of glycolysis, binding and silencing GLUT3, PFKP, PKM, HK2, and LDHA, such that loss-of-function elevates aerobic glycolysis and sensitizes tumors to glycolytic inhibition (PMID:25184678, PMID:26455326, PMID:37066523). In erythroid cells it is induced by KLF1 and directly represses fetal γ-globin (HBG1/HBG2) by binding two C:G quadruplets in the -200 bp promoter through ZF1, ZF2, and ZF4, a recognition mode resolved crystallographically and disrupted by HPFH point mutations (PMID:29296711, PMID:29610478, PMID:34592153). Beyond classical repression, ZBTB7A modulates partner transcription factors and signaling through direct protein–protein interactions with NF-κB p65, the androgen receptor, Smad4, ETS-1, and SREBP-1, and regulates BCL-X alternative splicing by interacting with SAM68 (PMID:15917220, PMID:18682402, PMID:20812024, PMID:24514149, PMID:25514493, PMID:31444154). Recurrent zinc-finger mutations that abolish DNA binding occur in t(8;21) AML and cooperate with RUNX1-RUNX1T1 to permit clonal expansion of hematopoietic progenitors, while context-dependent roles render ZBTB7A oncogenic or tumor-suppressive across cancer types (PMID:26455326, PMID:27252013, PMID:32115572).

Mechanistic history

Synthesis pass · year-by-year structured walk · 23 steps
  1. 1997 High

    Established ZBTB7A as a sequence-specific DNA-binding factor by identifying it as the cellular protein recognizing the HIV-1 IST element and linking its binding to transcriptional elongation control.

    Evidence Biochemical purification, protein-DNA crosslinking, and EMSA with IST mutants

    PMID:9199312

    Open questions at the time
    • Did not define the protein's domain architecture
    • Cellular target genes beyond the viral element unknown
  2. 1999 High

    Defined the bipartite architecture—N-terminal POZ/BTB domain mediating homomerization and four C-terminal zinc fingers sufficient for DNA binding—and showed physical association with HIV-1 Tat.

    Evidence cDNA cloning, domain deletion analysis, in vivo homomer detection, co-IP with Tat

    PMID:9973611

    Open questions at the time
    • Cellular corepressor partners not yet identified
    • DNA consensus not yet systematically defined
  3. 2002 High

    Revealed a non-canonical repression mode in which the POZ domain directly binds the Sp1 DNA-binding domain to evict Sp1 from GC boxes, establishing competitive repression independent of ZBTB7A's own DNA binding.

    Evidence GST pull-down, EMSA, DNase I footprinting, ChIP, and Gal4 reporter assay on ADH5/FDH promoter

    PMID:12004059

    Open questions at the time
    • Generality of Sp1 competition across promoters untested at the time
    • HDAC recruitment not yet shown
  4. 2003 Medium

    Characterized the flexible GC-rich consensus ZBTB7A recognizes and showed its induction promotes adipocyte differentiation while suppressing proliferation, framing it as a proliferation-to-differentiation switch.

    Evidence EMSA across binding sites; overexpression in 3T3-L1 with differentiation, lipid, and proliferation readouts

    PMID:12750370 PMID:14701838

    Open questions at the time
    • Adipogenesis data are overexpression gain-of-function
    • Direct target genes driving the differentiation switch not fully mapped
  5. 2005 High

    Defined ZBTB7A as a bona fide proto-oncogene by showing direct ARF repression, that its loss renders fibroblasts refractory to transformation, and that overexpression transforms cells and mice.

    Evidence ChIP, reporter assay, Zbtb7 KO MEF transformation assay, transgenic mouse model

    PMID:15662416

    Open questions at the time
    • Did not resolve the context-dependence (oncogene vs tumor suppressor) seen in later studies
    • Corepressor complex composition at ARF not detailed
  6. 2005 Medium

    Showed ZBTB7A also engages signaling transcription factors directly, binding NF-κB p65 via its POZ domain to enhance p65 stability and target gene transcription.

    Evidence Reciprocal co-IP, luciferase reporter, confocal microscopy

    PMID:15917220

    Open questions at the time
    • Single-laboratory interaction data
    • Whether p65 regulation is direct transcriptional or purely stability-based not fully separated
  7. 2006 High

    Established the structural basis of POZ/BTB homodimerization and demonstrated that the LRF BTB surface diverges from BCL6, explaining why the SMRT BCL6-binding peptide does not engage it.

    Evidence X-ray crystallography at 2.1 Å plus BBD peptide binding assay

    PMID:17189472

    Open questions at the time
    • Did not identify the actual corepressor-recruitment surface used by LRF
    • No DNA-bound structure
  8. 2008 High

    Mechanistically linked ZBTB7A repression to corepressor-HDAC recruitment, showing Rb, p21, cyclin A, and E2F-4 silencing through POZ-mediated Sin3A/HDAC1 binding, histone deacetylation, and Sp1 competition.

    Evidence ChIP, EMSA, reporter assays, mutagenesis, histone deacetylation and differentiation assays

    PMID:18368381 PMID:18801742

    Open questions at the time
    • Distinction between direct binding and Sp1 competition at each target not always resolved
    • In vivo relevance to differentiation tested only in cell models
  9. 2008 Medium

    Demonstrated context-dependent transcriptional activation, with ZBTB7A directly partnering SREBP-1 to synergistically activate FASN by remodeling Sp1/SREBP-1 promoter occupancy.

    Evidence Co-IP, ChIP, EMSA, reporter and co-transfection assays

    PMID:18682402

    Open questions at the time
    • Single-laboratory finding
    • How the repressor switches to a coactivator mode mechanistically unresolved
  10. 2009 High

    Positioned ZBTB7A as a master controller of the ARF–Hdm2–p53–p21 axis through direct p21 repression involving competition with both Sp1 and p53 and recruitment of mSin3A/NCoR/SMRT.

    Evidence ChIP, EMSA, reporter assays, co-IP, histone deacetylation assay; plus eEF1A/CCS-3 corepressor-bridging study

    PMID:19244234 PMID:19471103

    Open questions at the time
    • CCS-3 bridging interaction not independently replicated
    • Relative contribution of Sp1 vs p53 competition not quantified
  11. 2010 Medium

    Extended ZBTB7A's interactome to nuclear receptors, showing ligand-dependent corepression of the androgen receptor via a ternary AR–ZBTB7A–SMRT complex and HDAC-dependent inhibition.

    Evidence Co-IP, ChIP, reporter assays, HDAC inhibitor treatment in prostate cancer cells

    PMID:20812024

    Open questions at the time
    • Single-laboratory interaction data
    • Endogenous target gene scope limited to PSA
  12. 2011 High

    Identified tissue-specific roles in bone and demonstrated activating as well as repressive functions in cancer, showing requirement for RANKL-induced osteoclastogenesis and direct activation of survivin and MT1-MMP to promote invasion.

    Evidence Transgenic mouse, siRNA knockdown, histomorphometry; ChIP, mutagenesis, reporter, invasion assays

    PMID:21176152 PMID:21392388 PMID:21590684

    Open questions at the time
    • Mechanistic basis for activation vs repression at different promoters not unified
    • Survivin and MT1-MMP activation from single laboratories
  13. 2012 Medium

    Showed ZBTB7A enforces survival and apoptosis resistance by directly repressing the pro-apoptotic Bim gene and by acting in a homeostatic NF-κB feedback loop activating p65 and IκBα promoters.

    Evidence ChIP, reporter assays, knockdown, flow cytometry, caspase-3 assays

    PMID:22754333 PMID:23054188

    Open questions at the time
    • Single-laboratory studies
    • Whether p65/IκBα activation is direct in physiological settings unconfirmed
  14. 2013 High

    Uncovered DNA-methylation-based silencing by ZBTB7A through direct MBD3 interaction recruiting the Mi-2/NuRD-HDAC complex and BCoR-linked DNMTs/HP1 to CDKN1A, and revealed context-dependent tumor suppression via SOX9 antagonism.

    Evidence Co-IP, ChIP, methylated/non-methylated EMSA, reporter; conditional prostate Zbtb7a KO with target gene analysis

    PMID:23300578 PMID:23355454 PMID:23658227 PMID:23727861

    Open questions at the time
    • Direct demonstration of DNMT-mediated methylation at the locus inferred from interactions
    • Reconciliation of oncogenic ARF-repression with tumor-suppressive senescence bypass left to context
  15. 2014 High

    Defined ZBTB7A as a direct transcriptional repressor of glycolysis (GLUT3, PFKP, PKM) whose loss elevates glycolytic flux, and revealed a non-transcriptional role regulating BCL-X splicing via SAM68.

    Evidence ChIP, reporter, metabolic assays, KO/KD cell and mouse models, TCGA analysis; co-IP, RIP, splicing assays, HDAC inhibitor

    PMID:24514149 PMID:24857950 PMID:25184678 PMID:25514493

    Open questions at the time
    • Smad4 and ETS-1 interactions are single-laboratory (ETS-1 low confidence)
    • Mechanistic link between HDAC activity and splicing control incompletely defined
  16. 2015 High

    Tied loss of ZBTB7A DNA binding to malignancy, showing cancer-derived zinc-finger mutations abolish binding, de-repress glycolytic targets, and enhance proliferation, and that ZBTB7A represses MCAM to restrain metastasis.

    Evidence Zinc-finger mutagenesis, reporter and metabolic assays, genome database mining; ChIP, reporter, invasion assays, melanoma specimens

    PMID:25995384 PMID:26455326

    Open questions at the time
    • Structural consequences of mutations not yet resolved at this stage
    • MCAM repression from single laboratory
  17. 2016 High

    Established ZBTB7A as a recurrently mutated gene in t(8;21) AML, with C-terminal zinc-finger mutations disrupting repressor and anti-proliferative activity, implying leukemogenic cooperation with RUNX1/RUNX1T1.

    Evidence Patient sequencing (23% of t(8;21) AML), reporter and proliferation assays of mutants

    PMID:27252013

    Open questions at the time
    • Direct functional cooperation with RUNX1-RUNX1T1 not yet demonstrated experimentally at this point
    • Key downstream effector of the leukemic phenotype not pinpointed
  18. 2017 Medium

    Identified upstream regulation in erythroid cells (KLF1-driven expression of a novel transcript) and additional lineage-specific repressive targets, broadening the regulatory circuitry around ZBTB7A.

    Evidence ChIP, transcript analysis in erythroid differentiation; ChIP/reporter/RNA-IP in osteosarcoma (LINC00473)

    PMID:28942243 PMID:29296711

    Open questions at the time
    • Functional consequence of the erythroid-specific transcript not fully defined
    • Single-laboratory target studies
  19. 2018 High

    Established ZBTB7A as a major direct repressor of fetal γ-globin via the -200 bp promoter element and, genome-wide, as a chromatin accessibility transducer required for NF-κB-driven inducible accessibility changes.

    Evidence CRISPR HPFH mutations, ChIP, EMSA, erythroid reporters; genome-wide ChIP-seq/ATAC-seq/RNA-seq with knockdown and p65 induction

    PMID:29610478 PMID:29764865 PMID:29813070

    Open questions at the time
    • Mechanism by which ZBTB7A marks promoters for client-TF accessibility not molecularly resolved
    • HP1γ–ZBTB7A axis from single laboratory
  20. 2019 High

    Refined ZBTB7A's role in nuclear-receptor and metabolic circuits, showing AR-directed recruitment to E2F-Rb sites to suppress replication genes, reciprocal regulation with ERα/TRIM25, and hypoxic NF-κB repression de-repressing the MCT4 lactate exporter.

    Evidence ChIP-seq, RNA-seq, co-IP, xenografts; reporter, ubiquitination, ChIP, oligonucleotide pulldown assays

    PMID:30265334 PMID:30753838 PMID:31271899 PMID:31444154 PMID:31715186

    Open questions at the time
    • Most signaling-loop studies from single laboratories
    • Integration of these loops into a unified regulatory logic incomplete
  21. 2020 High

    Demonstrated ZBTB7A's role in cell-fate chromatin remodeling during pluripotency transitions and functionally confirmed t(8;21) leukemic cooperativity, with WT ZBTB7A blocking RUNX1-RUNX1T1-driven clonal expansion through glycolysis-coupled cell-cycle arrest.

    Evidence ATAC-seq/ChIP-seq/RNA-seq in BMP4-driven PNT; lentiviral WT/mutant expression in CD34+ cells, Seahorse, cell cycle, 2-DG

    PMID:32115572 PMID:32393886

    Open questions at the time
    • Dual opening/silencing activity during PNT mechanistically unexplained
    • Molecular link between glycolysis repression and cell-cycle arrest in leukemia not fully traced
  22. 2021 High

    Resolved the atomic basis of γ-globin repression, showing ZF1/ZF2 read the 5' C:G quadruplet and ZF4 the 3' quadruplet, and that the most disruptive HPFH mutations hit ZF1/ZF2-recognized bases.

    Evidence X-ray crystallography of the four-zinc-finger DBD bound to the -200 bp element plus mutant binding assays

    PMID:34592153

    Open questions at the time
    • Structure of the full-length protein or POZ-mediated complexes on DNA not solved
    • Does not address corepressor recruitment geometry
  23. 2023 Medium

    Extended ZBTB7A's tumor-suppressive and metabolic repertoire to glioblastoma, showing direct repression of EPB41L5 (restraining EMT) and of HK2/LDHA (limiting glycolysis), with non-coding RNAs destabilizing ZBTB7A to release these programs.

    Evidence ChIP, RNA-seq, 3'UTR reporter, Seahorse, knockdown, in vivo tumor assays

    PMID:36243002 PMID:36596853 PMID:37066523

    Open questions at the time
    • GBM target studies from single laboratories
    • Connection between oxidative-stress control in viral persistence and canonical transcription functions unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • How ZBTB7A integrates its opposing activator/repressor and oncogenic/tumor-suppressive outputs—and what determines whether it opens or silences chromatin at a given locus as an accessibility transducer—remains unresolved.
  • No unifying model for context-dependent activation vs repression
  • Molecular determinants of promoter selection for TF-induced accessibility unknown
  • Structure of POZ-corepressor complexes on chromatin not defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 6 GO:0003677 DNA binding 4 GO:0098772 molecular function regulator activity 4 GO:0140098 catalytic activity, acting on RNA 1
Localization
GO:0005634 nucleus 3 GO:0005654 nucleoplasm 1
Pathway
R-HSA-74160 Gene expression (Transcription) 6 R-HSA-1640170 Cell Cycle 5 R-HSA-1430728 Metabolism 4 R-HSA-162582 Signal Transduction 4 R-HSA-1643685 Disease 3 R-HSA-4839726 Chromatin organization 3
Partners
ARKHDRBS1MBD3RELASMAD4SOX9SP1SREBF1
Complex memberships
Mi-2/NuRD-HDAC complex (via MBD3)NCoR/SMRT corepressor complexSin3A-HDAC corepressor complexZBTB7A POZ-domain homodimer

Evidence

Reading pass · 47 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 FBI-1 (ZBTB7A) was purified as a cellular factor that specifically binds to the HIV-1 inducer of short transcripts (IST), a bipartite DNA element downstream of the HIV-1 transcriptional start site; binding of FBI-1 to IST correlates with the ability of IST mutants to direct abortive (short) transcript synthesis, suggesting FBI-1 promotes transcription elongation blocks. Biochemical purification, specific protein-DNA crosslinking, EMSA with IST mutants Molecular and cellular biology High 9199312
1999 FBI-1 (ZBTB7A) contains an N-terminal POZ/BTB domain and four C-terminal Krüppel-type zinc fingers; the C-terminus is sufficient for specific DNA binding, and FBI-1 forms homomers through its POZ domain (and in vivo through its zinc finger domain); FBI-1 also physically associates with HIV-1 Tat protein. cDNA cloning, domain deletion analysis, in vivo homomer detection, co-immunoprecipitation with Tat Nucleic acids research High 9973611
2002 The POZ domain of FBI-1 (ZBTB7A) directly interacts with the zinc finger DNA-binding domain of Sp1, preventing Sp1 from binding GC boxes on the ADH5/FDH promoter, thereby repressing transcription; this mechanism was shared by the POZ domains of PLZF and BCL-6. GST pull-down (POZ domain fusions), EMSA, DNase I footprinting, ChIP, Gal4 fusion reporter assay The Journal of biological chemistry High 12004059
2002 FBI-1 stimulates HIV-1 Tat-activated transcription; this effect requires the same FBI-1 domain that mediates physical Tat–FBI-1 association in vivo. FBI-1 partially co-localizes with Tat and P-TEFb (Cdk9/CyclinT1) at nuclear speckles, and its nuclear distribution depends on its DNA-binding domain, cellular DNA, and active transcription. Transcription reporter assay, co-immunoprecipitation, confocal microscopy/immunofluorescence co-localization Molecular biology of the cell Medium 11907272
2003 FBI-1 (ZBTB7A) binds to inverted, direct, and everted sequence repeats with the consensus G(A/G)GGG(T/C)(C/T)(T/C)(C/T) with high flexibility in orientation and spacing, indicating highly flexible DNA recognition by a POZ-domain protein. EMSA with multiple viral and cellular binding sites, sequence analysis The Journal of biological chemistry Medium 12750370
2003 FBI-1 (ZBTB7A) is induced during early human and murine preadipocyte differentiation and promotes adipogenesis; stably overexpressing FBI-1 in 3T3-L1 cells accelerated differentiation markers and lipid accumulation while reducing DNA synthesis and cyclin A expression, placing FBI-1 as a dual regulator switching cells from proliferation to differentiation. Stable cell line overexpression, quantification of differentiation markers, lipid accumulation assay, cell proliferation assay, cyclin A protein measurement The Journal of biological chemistry Medium 14701838
2005 Pokemon/ZBTB7A directly represses ARF tumor suppressor gene transcription through direct promoter binding; mouse embryonic fibroblasts lacking Zbtb7 are completely refractory to oncogene-mediated transformation, and Pokemon overexpression causes oncogenic transformation in vitro and in transgenic mice. ChIP, promoter reporter assay, MEF transformation assay, Zbtb7 knockout MEFs, transgenic mouse model Nature High 15662416
2005 FBI-1 (ZBTB7A) interacts with the Rel homology domain of NF-κB p65 via its POZ domain in vivo and in vitro, enhances NF-κB-mediated E-selectin gene transcription, promotes nuclear localization and stability of p65, and also interacts with IκBα and IκBβ. Co-immunoprecipitation (in vivo and in vitro protein-protein interaction), luciferase reporter assay, confocal microscopy The Journal of biological chemistry Medium 15917220
2006 The BTB/POZ domain of human LRF/ZBTB7A adopts the canonical BTB homodimer fold; the lateral groove and charged pocket on the homodimer surface differ substantially from BCL6 BTB, and the 17-residue BCL6 Binding Domain (BBD) of SMRT co-repressor does not bind to the LRF BTB domain. X-ray crystallography (2.1 Å), in vitro binding assay (BBD peptide binding test) Protein science High 17189472
2008 FBI-1 (ZBTB7A) represses Rb gene transcription by binding to four GC-rich FBI-1-response elements (FREs) in the Rb promoter and by competing with Sp1 at GC-box 2 and FRE3; repression involves recruitment of a co-repressor–HDAC complex through the POZ domain, leading to deacetylation of H3 and H4 histones at the Rb promoter. FBI-1 also inhibits C2C12 myoblast differentiation by repressing Rb. ChIP, EMSA, luciferase reporter assay, site-directed mutagenesis, histone deacetylation assay, myoblast differentiation assay The Journal of biological chemistry High 18801742
2008 FBI-1 (ZBTB7A) and SREBP-1 interact directly via their DNA-binding domains and synergistically activate FASN gene transcription; FBI-1 alters the binding pattern of Sp1 and SREBP-1 on GC-box and SRE/E-box elements to drive higher Sp1 binding to the proximal FASN promoter. Co-immunoprecipitation, luciferase reporter assay, ChIP, EMSA, co-transfection experiments The Journal of biological chemistry Medium 18682402
2008 FBI-1 (ZBTB7A) acts as a dual regulator in adipogenesis: it represses cyclin A through an indirect mechanism (inhibiting Sp1 binding at the cyclin A promoter) and represses E2F-4 directly via a FBI-1 binding element; FBI-1 binds Sin3A and HDAC-1 to form a repressor complex through its POZ domain. Luciferase reporter assay, EMSA, co-immunoprecipitation, site-directed mutagenesis, POZ domain deletion mutants Journal of molecular medicine Medium 18368381
2009 FBI-1 (ZBTB7A) represses p21CIP1 transcription by direct binding to the proximal Sp1-3 GC-box and distal p53-responsive elements, competing with both Sp1 and p53; it also recruits co-repressors mSin3A, NCoR, and SMRT, leading to deacetylation of Ac-H3 and Ac-H4 histones at the p21 promoter. FBI-1 functions as a master controller of the ARF–Hdm2–p53–p21 pathway. ChIP, EMSA, luciferase reporter assay, co-immunoprecipitation, histone deacetylation assay The Journal of biological chemistry High 19244234
2009 eEF1A/CCS-3 directly interacts with FBI-1 (ZBTB7A) through both the zinc finger and POZ domains of FBI-1; CCS-3 enhances FBI-1-mediated transcriptional repression of p21CIP1 by facilitating interaction with co-repressors SMRT and BCoR at the POZ domain. Co-immunoprecipitation, GST pull-down, MALDI-TOF mass spectrometry, immunofluorescence co-localization, luciferase reporter assay Cellular physiology and biochemistry Medium 19471103
2010 FBI-1 (ZBTB7A) acts as a co-repressor of the androgen receptor (AR) in prostate cancer cells; FBI-1 physically interacts with AR in a ligand-dependent manner and forms a ternary complex with AR and SMRT, enhancing recruitment of NCoR and SMRT to endogenous PSA upstream sequences. FBI-1-mediated inhibition of AR transcriptional activity is partially dependent on HDAC activity. Co-immunoprecipitation, ChIP, luciferase reporter assay, HDAC inhibitor treatment Cellular and molecular life sciences Medium 20812024
2011 ZBTB7A/LRF (FBI-1/OCZF) is expressed in osteoclasts, is upregulated by RANKL in primary macrophages, and is required for RANKL-induced osteoclast formation in vitro; transgenic mice overexpressing OCZF under the cathepsin K promoter show decreased bone volume, increased osteoclast number, and promoted osteoclast survival. Immunostaining, in situ hybridization, transgenic mouse model (OCZF-Tg), siRNA knockdown of LRF in osteoclast differentiation assay, bone histomorphometry, pQCT Arthritis and rheumatism High 21590684
2011 Pokemon/ZBTB7A directly binds GT boxes in the survivin promoter and induces survivin expression in breast cancer cells; ChIP and site-directed mutagenesis confirmed direct promoter binding. ChIP, site-directed mutagenesis, DNA microarray, luciferase reporter Breast cancer research Medium 21392388
2011 FBI-1 (ZBTB7A) directly activates MT1-MMP promoter transcription by binding the ~600 bp 5'-flanking sequence of MT1-MMP (confirmed by promoter reporter assay and ChIP), leading to enhanced cancer cell migration and invasion; MT1-MMP knockdown abolished FBI-1-mediated invasion. ChIP, promoter reporter assay (promoter deletion constructs), siRNA knockdown of MT1-MMP, invasion/migration assay Molecular cancer Medium 21176152
2012 Pokemon/ZBTB7A directly binds the Bim promoter and suppresses Bim transcription, rendering liver cells resistant to anoikis; Pokemon knockdown enhances sensitivity to anoikis and chemical apoptotic stress, while ectopic Pokemon expression confers anoikis resistance. Dual-luciferase reporter assay, ChIP, siRNA knockdown, flow cytometry, caspase-3 activity assay International journal of molecular sciences Medium 22754333
2012 Pokemon/ZBTB7A directly binds the p65 promoter element at -434 to -430 bp and the IκBα promoter element at -453 to -448 bp, activating transcription of both, revealing a homeostatic regulatory role in NF-κB signaling. ChIP, targeted mutagenesis, luciferase reporter assay, siRNA knockdown Molecular and cellular biochemistry Medium 23054188
2013 FBI-1 (ZBTB7A) directly interacts with MBD3 in the nucleus; through MBD3, FBI-1 recruits the Mi-2/NuRD-HDAC complex to the CDKN1A promoter for epigenetic repression; MBD3 modulates FBI-1 interactions with co-repressors (decreasing NCoR/SMRT interaction, increasing BCoR interaction); BCoR links to DNMTs and HP1, enabling DNA methylation-based silencing of p21WAF/CDKN1A. Co-immunoprecipitation, ChIP, EMSA (methylated and non-methylated DNA binding), luciferase reporter assay Nucleic acids research High 23658227
2013 ZBTB7A physically interacts with SOX9 and functionally antagonizes SOX9 transcriptional activity on target genes MIA (tumor invasion) and H19 (lncRNA precursor for RB-targeting miRNA); prostate-specific Zbtb7a inactivation accelerates Pten loss-driven tumorigenesis through bypass of Pten loss-induced cellular senescence, Rb downregulation, and invasive cancer. Co-immunoprecipitation (physical interaction), conditional knockout mouse model (prostate-specific), RT-PCR/Western blot of target gene expression, histopathological analysis Nature genetics High 23727861
2013 Pokemon/ZBTB7A silencing in HCC inhibits the PI3K/Akt and c-Raf/MEK/ERK pathways and modulates cell cycle regulators, suppressing cell proliferation and migration in vitro and tumor growth in xenograft mice. Stable shRNA knockdown, Western blot (pathway markers), cell proliferation and migration assays, xenograft mouse model PloS one Medium 23300578
2013 Pokemon/ZBTB7A directly binds the miR-21 promoter at GC boxes (-684 to -679 bp and -652 to -647 bp) and upregulates miR-21 transcription, which in turn suppresses Sprouty1 (a miR-21 target); site-directed mutagenesis of GC boxes abolished Pokemon regulation of miR-21. ChIP, luciferase reporter assay, site-directed mutagenesis, siRNA Journal of cellular biochemistry Medium 23355454
2014 ZBTB7A directly binds to the promoters of key glycolytic genes GLUT3, PFKP, and PKM and transcriptionally represses them; ZBTB7A-deficient tumors exhibit elevated glycolysis and heightened sensitivity to glycolysis inhibition. ChIP, luciferase reporter assay, metabolic assays, ZBTB7A loss-of-function (KO/KD) in cell lines and mouse models, TCGA data analysis Genes & development High 25184678
2014 FBI-1 (ZBTB7A) interacts with the splicing factor SAM68 and reduces SAM68 binding to BCL-X mRNA, shifting BCL-X alternative splicing toward the anti-apoptotic BCL-XL variant and counteracting SAM68-mediated apoptosis; this splicing role requires HDAC activity. Co-immunoprecipitation, RNA immunoprecipitation, RT-PCR splicing assay, FBI-1 knockdown, SAM68 interaction-domain mutant, HDAC inhibitor treatment EMBO reports High 24514149
2014 Pokemon/ZBTB7A directly interacts with Smad4, and this interaction is enhanced by TGF-β1 treatment; Pokemon overexpression decreases TGF-β-induced transcriptional activities by recruiting HDAC1 to the Smad4 complex and reducing Smad4–p300/CBP interaction, without affecting Smad2/3 activation or Smad complex formation. Co-immunoprecipitation (in vitro and in vivo), luciferase reporter assay, ChIP (Pokemon recruitment to Smad4-DNA complex), Western blot Biochimica et biophysica acta Medium 25514493
2014 FBI-1 (ZBTB7A) physically interacts with ETS-1, promotes ETS-1 nuclear accumulation, and enhances ETS-1 recruitment to target gene promoters; this occurs partly by FBI-1 downregulating p53-mediated inhibition of ETS-1. Co-immunoprecipitation, ChIP, luciferase reporter assay PloS one Low 24857950
2015 ZBTB7A directly binds the MCAM promoter and transcriptionally represses MCAM expression; loss of ZBTB7A leads to upregulation of MCAM and enhanced melanoma cell invasion and metastasis. ChIP, promoter reporter assay, loss-of-function (ZBTB7A KD), invasion/metastasis assays, human melanoma specimen analysis Molecular cancer research Medium 25995384
2015 Zinc finger domain mutations in ZBTB7A (identified in human cancers) result in loss of DNA-binding function; cells harboring these mutations show marked upregulation of glycolytic target genes (GLUT3, PFKP, PKM), increased glycolysis, and enhanced proliferation. Site-directed mutagenesis of zinc finger domain, luciferase reporter assay, metabolic assays, cell proliferation assay, cancer genome database mining Oncogene High 26455326
2016 Recurrent ZBTB7A mutations (missense and truncating) affecting the C-terminal zinc-finger domain occur in 23% of AML t(8;21) patients; these mutations disrupt the transcriptional repressor activity and anti-proliferative effect of ZBTB7A, and their specific association with t(8;21) AML indicates leukaemogenic cooperativity with RUNX1/RUNX1T1. Sequencing of patient samples, functional luciferase reporter assay (repressor activity), proliferation assay of mutant ZBTB7A-expressing cells Nature communications High 27252013
2017 KLF1 directly drives ZBTB7A expression in erythroid cells by binding to the ZBTB7A proximal promoter (confirmed by ChIP); an erythroid-specific regulatory mechanism upregulates a novel ZBTB7A transcript in the erythroid compartment. ChIP, promoter analysis, RT-PCR of novel transcript, erythroid cell differentiation system Blood advances Medium 29296711
2017 ZBTB7A directly binds the LINC00473 promoter and transcriptionally represses LINC00473 expression in osteosarcoma; LINC00473 interacts with transcription factor C/EBPβ, facilitating its binding to the IL24 promoter to decrease chemoresistance. ChIP, luciferase reporter assay, siRNA knockdown, RNA immunoprecipitation Neoplasia Medium 28942243
2017 Zbtb7a induction in alveolar macrophages (AMs) is a critical early event in DSA-induced chronic lung allograft rejection; selective disruption of Zbtb7a in AMs reduced bronchiolar occlusion and immune responses to lung-restricted self-antigens; antigen presentation by AMs is Zbtb7a-dependent, as Zbtb7a-deficient AMs failed to induce antibody and T cell responses. Conditional macrophage-specific Zbtb7a knockout, murine obliterative airway disease model, adoptive transfer, immunological readouts (antibody and T cell responses) Science translational medicine High 28701473
2018 ZBTB7A directly binds the γ-globin gene promoter at the -200 bp region (containing two copies of four consecutive C:G base pairs) and acts as a major direct repressor of fetal HBG1/HBG2 (γ-globin) gene expression; naturally occurring HPFH-associated point mutations at -200 bp disrupt ZBTB7A binding and elevate γ-globin expression. CRISPR-Cas9 introduction of HPFH mutations, ChIP, EMSA, erythroid cell reporter assays Nature genetics High 29610478
2018 HP1γ (CBX3) directly represses ZBTB7A expression in lung adenocarcinoma cells; knockdown of ZBTB7A significantly restores the proliferation, colony formation, and migration defects caused by HP1γ depletion, placing ZBTB7A downstream of HP1γ in a lung adenocarcinoma-promoting pathway; ZBTB7A in turn downregulates AXL expression. siRNA knockdown (HP1γ and ZBTB7A), epistasis rescue experiment, ChIP (HP1γ on ZBTB7A locus), cell proliferation/colony/migration assays, in vivo K-RasG12D mouse model Cancer research Medium 29764865
2018 Zbtb7a binds to a significant fraction of genomic promoters and enhancers genome-wide; it is required for inducible changes in chromatin accessibility driven by NF-κB p65 and other transcription factors (TFs); Zbtb7a associates with promoters independently of client TF binding and specifies promoters amenable to TF-induced accessibility changes, acting as an accessibility transducer. ChIP-seq, ATAC-seq, RNA-seq, Zbtb7a knockdown, p65 induction experiments in macrophages PLoS biology High 29813070
2019 ZBTB7A mediates AR-dependent transcriptional repression in prostate cancer cells; ZBTB7A is recruited to E2F-Rb binding sites by AR and negatively regulates E2F1 transcriptional activity on DNA replication genes; AR recruitment of Rb strengthens the E2F-Rb repression complex; ZBTB7A suppresses castration-resistant prostate cancer growth in vitro and in vivo. ChIP-seq, RNA-seq, siRNA knockdown, co-immunoprecipitation, in vitro and xenograft in vivo assays Cancer research High 31444154
2019 Under hypoxia, NF-κB (RelA/p65) binds NF-κB-binding elements in the ZBTB7A promoter and represses ZBTB7A expression, thereby de-repressing SLC16A3 (MCT4); FBI-1/ZBTB7A directly represses SLC16A3 by binding both FREs and HREs in the SLC16A3 promoter during normoxia. Transient transfection/reporter assay of SLC16A3 and ZBTB7A promoter constructs, oligonucleotide pulldown, ChIP Biochimica et biophysica acta. Gene regulatory mechanisms Medium 31271899
2019 ZBTB7A transcriptionally regulates ERα (ESR1) expression in ERα-positive breast cancer by binding the ESR1 promoter (+146 to +461 bp downstream of TSS), and inhibition of ZBTB7A upregulates E3 ligase TRIM25, enhancing ERα ubiquitination and proteasomal degradation; ERα in turn potentiates ZBTB7A expression post-translationally, forming a positive feedback loop. ChIP, luciferase reporter assay, siRNA knockdown, TRIM25 co-IP/ubiquitination assay, estrogen-response element reporter Journal of molecular cell biology / Life sciences Medium 30265334 31715186
2019 ZBTB7A directly binds the LncRNA GAS5 promoter and transcriptionally suppresses GAS5 expression in osteosarcoma cells, reducing ER stress-induced apoptosis; miR-663a (induced by ER stress) directly targets the 3'UTR of ZBTB7A to downregulate it. ChIP, luciferase reporter assay, miRNA 3'UTR reporter assay, siRNA knockdown, in vivo xenograft Cancer letters Medium 30753838
2020 BMP4 signaling opens chromatin at Zbtb7a/b loci early during primed-to-naive pluripotency transition (PNT); ZBTB7A in turn occupies and facilitates opening of naive pluripotent chromatin loci (activating nearby genes) while also occupying loci that are silenced, consistent with dual roles in chromatin remodeling during PNT. ATAC-seq (chromatin accessibility), ChIP-seq (ZBTB7A binding), RNA-seq, BMP4-driven PNT system, ZBTB7A overexpression/knockdown Nature cell biology High 32393886
2020 Wild-type ZBTB7A prevents RUNX1-RUNX1T1 (AML1-ETO)-mediated clonal expansion of human CD34+ hematopoietic stem and progenitor cells; ZBTB7A mutations enable this clonal expansion. ZBTB7A loss increases glycolysis and sensitizes t(8;21) leukemic blasts to 2-deoxy-D-glucose. ZBTB7A expression in t(8;21) cells causes cell cycle arrest recapitulated by glycolysis inhibition. Lentiviral expression of WT/mutant ZBTB7A in CD34+ cells, clonal expansion assay, Seahorse metabolic assay, cell cycle analysis, 2-DG treatment Oncogene High 32115572
2021 X-ray crystal structures of the ZBTB7A DNA-binding domain (four zinc fingers) in complex with the γ-globin promoter -200 bp element reveal that ZF1 and ZF2 recognize the 5' C:G quadruple and ZF4 contacts the 3' C:G quadruple; HPFH-associated mutations that impair ZBTB7A binding most severely disrupt base pairs recognized by ZF1 and ZF2. X-ray crystallography, in vitro DNA-binding assays with HPFH mutant sequences Cell reports High 34592153
2022 CRISPR activation screen identified ZBTB7A as a factor that, when upregulated, promotes cell survival and allows HCoV-229E to establish a persistent homeostatic infection rather than causing cell death; control of oxidative stress is a primary driver of cellular survival during HCoV-229E infection downstream of ZBTB7A. CRISPR activation screen, viral infection assay (HCoV-229E), cell viability assay, oxidative stress measurement Cell reports Medium 36243002
2023 ZBTB7A directly binds the EPB41L5 gene promoter and represses its transcription in glioblastoma cells; ZBTB7A depletion induces GBM progression and metastasis, while ZBTB7A expression dramatically inhibits GBM tumor growth by suppressing EPB41L5-driven EMT. RNA-seq (ZBTB7A-depleted vs. control), ChIP (ZBTB7A binding to EPB41L5 promoter), loss-of-function (siRNA/shRNA), in vitro invasion assay, in vivo tumor growth assay Experimental & molecular medicine Medium 36596853
2023 ZBTB7A directly binds the promoter regions of HK2 and LDHA, transcriptionally inhibiting their expression; small nucleolar RNA-derived fragment U3-miR reduces ZBTB7A mRNA stability (via ZBTB7A 3'UTR binding), thereby releasing HK2/LDHA repression and enhancing aerobic glycolysis in IDH1-wild-type glioblastoma cells. ChIP (ZBTB7A on HK2 and LDHA promoters), luciferase 3'UTR reporter assay, Seahorse glycolysis assay, siRNA knockdown CNS neuroscience & therapeutics Medium 37066523

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 276 15662416
2018 Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nature genetics 247 29610478
2013 Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nature genetics 122 23727861
2014 ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis. Genes & development 93 25184678
2008 Proto-oncogene FBI-1 (Pokemon/ZBTB7A) represses transcription of the tumor suppressor Rb gene via binding competition with Sp1 and recruitment of co-repressors. The Journal of biological chemistry 84 18801742
2005 The transcription factor Pokemon: a new key player in cancer pathogenesis. Cancer research 84 16204018
2002 POZ domain transcription factor, FBI-1, represses transcription of ADH5/FDH by interacting with the zinc finger and interfering with DNA binding activity of Sp1. The Journal of biological chemistry 83 12004059
2009 Proto-oncogene FBI-1 represses transcription of p21CIP1 by inhibition of transcription activation by p53 and Sp1. The Journal of biological chemistry 73 19244234
1997 Purification and characterization of FBI-1, a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts. Molecular and cellular biology 70 9199312
2008 Proto-oncogene FBI-1 (Pokemon) and SREBP-1 synergistically activate transcription of fatty-acid synthase gene (FASN). The Journal of biological chemistry 68 18682402
2018 HP1γ Promotes Lung Adenocarcinoma by Downregulating the Transcription-Repressive Regulators NCOR2 and ZBTB7A. Cancer research 67 29764865
2021 Capsaicin Inhibits Proliferation and Induces Apoptosis in Breast Cancer by Down-Regulating FBI-1-Mediated NF-κB Pathway. Drug design, development and therapy 64 33469265
2013 Role of LRF/Pokemon in lineage fate decisions. Blood 64 23396304
2007 Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer. The Journal of pathology 59 17907153
2017 LncRNA CCAT2 promotes tumorigenesis by over-expressed Pokemon in non-small cell lung cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 55 28088736
2015 C/EBPα-induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer. Cancer letters 55 26404754
2014 The transcription factor FBI-1 inhibits SAM68-mediated BCL-X alternative splicing and apoptosis. EMBO reports 55 24514149
2010 FBI-1 functions as a novel AR co-repressor in prostate cancer cells. Cellular and molecular life sciences : CMLS 54 20812024
2016 ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation. Nature communications 51 27252013
2020 BMP4 resets mouse epiblast stem cells to naive pluripotency through ZBTB7A/B-mediated chromatin remodelling. Nature cell biology 50 32393886
2011 Pro-oncogene Pokemon promotes breast cancer progression by upregulating survivin expression. Breast cancer research : BCR 49 21392388
2010 Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers. Experimental and molecular pathology 49 20471975
2003 Role of the POZ zinc finger transcription factor FBI-1 in human and murine adipogenesis. The Journal of biological chemistry 49 14701838
2017 KLF1 directly activates expression of the novel fetal globin repressor ZBTB7A/LRF in erythroid cells. Blood advances 48 29296711
2005 FBI-1 enhances transcription of the nuclear factor-kappaB (NF-kappaB)-responsive E-selectin gene by nuclear localization of the p65 subunit of NF-kappaB. The Journal of biological chemistry 48 15917220
2006 Crystal structure of the BTB domain from the LRF/ZBTB7 transcriptional regulator. Protein science : a publication of the Protein Society 47 17189472
1999 FBI-1, a factor that binds to the HIV-1 inducer of short transcripts (IST), is a POZ domain protein. Nucleic acids research 47 9973611
2002 FBI-1 can stimulate HIV-1 Tat activity and is targeted to a novel subnuclear domain that includes the Tat-P-TEFb-containing nuclear speckles. Molecular biology of the cell 45 11907272
2017 ZBTB7A Enhances Osteosarcoma Chemoresistance by Transcriptionally Repressing lncRNALINC00473-IL24 Activity. Neoplasia (New York, N.Y.) 44 28942243
2019 ZBTB7A, a miR-663a target gene, protects osteosarcoma from endoplasmic reticulum stress-induced apoptosis by suppressing LncRNA GAS5 expression. Cancer letters 43 30753838
2020 Emerging role of ZBTB7A as an oncogenic driver and transcriptional repressor. Cancer letters 42 32348807
2013 The proto-oncoprotein FBI-1 interacts with MBD3 to recruit the Mi-2/NuRD-HDAC complex and BCoR and to silence p21WAF/CDKN1A by DNA methylation. Nucleic acids research 42 23658227
2010 Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Molecular cancer 39 21176152
2018 Zbtb7a is a transducer for the control of promoter accessibility by NF-kappa B and multiple other transcription factors. PLoS biology 37 29813070
2017 "Pokémon Go!" May Promote Walking, Discourage Sedentary Behavior in College Students. Games for health journal 37 28628384
2019 Hypoxia-induced RelA/p65 derepresses SLC16A3 (MCT4) by downregulating ZBTB7A. Biochimica et biophysica acta. Gene regulatory mechanisms 36 31271899
2011 FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo. Cancer 36 21713761
2008 Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results. Lung cancer (Amsterdam, Netherlands) 36 18550205
2020 FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis. Cell death & disease 35 33051436
2019 The multi-faceted functioning portrait of LRF/ZBTB7A. Human genomics 35 31823818
2015 Somatic human ZBTB7A zinc finger mutations promote cancer progression. Oncogene 35 26455326
2012 The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway. PloS one 35 23300578
2003 Flexible DNA binding of the BTB/POZ-domain protein FBI-1. The Journal of biological chemistry 35 12750370
2014 Pokemon (FBI-1) interacts with Smad4 to repress TGF-β-induced transcriptional responses. Biochimica et biophysica acta 34 25514493
2017 MicroRNA-520e suppresses non-small-cell lung cancer cell growth by targeting Zbtb7a-mediated Wnt signaling pathway. Biochemical and biophysical research communications 33 28242196
2008 Transcription factor FBI-1 acts as a dual regulator in adipogenesis by coordinated regulation of cyclin-A and E2F-4. Journal of molecular medicine (Berlin, Germany) 33 18368381
2015 ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. Molecular cancer research : MCR 32 25995384
2013 microRNA 21-mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation. Journal of cellular biochemistry 32 23355454
2010 ZBTB7 overexpression contributes to malignancy in breast cancer. Cancer investigation 30 20394500
2013 Silencing of Pokemon enhances caspase-dependent apoptosis via fas- and mitochondria-mediated pathways in hepatocellular carcinoma cells. PloS one 28 23874836
2021 Structural basis for human ZBTB7A action at the fetal globin promoter. Cell reports 27 34592153
2019 ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. Cancer research 27 31444154
2015 A Zbtb7a proto-oncogene as a novel target for miR-125a. Molecular carcinogenesis 26 26713860
2009 Curcumin decreases the expression of Pokemon by suppressing the binding activity of the Sp1 protein in human lung cancer cells. Molecular biology reports 26 19444642
2017 Who Is Still Playing Pokémon Go? A Web-Based Survey. JMIR serious games 25 28381393
2011 The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo. Arthritis and rheumatism 25 21590684
2019 ZBTB7A promotes migration, invasion and metastasis of human breast cancer cells through NF-κB-induced epithelial-mesenchymal transition in vitro and in vivo. Journal of biochemistry 24 31385585
2018 Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Annals of hematology 24 30251205
2021 Role of ZBTB7A zinc finger in tumorigenesis and metastasis. Molecular biology reports 23 34014468
2012 Homeostatic regulatory role of Pokemon in NF-κB signaling: stimulating both p65 and IκBα expression in human hepatocellular carcinoma cells. Molecular and cellular biochemistry 23 23054188
2020 The miR-372-ZBTB7A Oncogenic Axis Suppresses TRAIL-R2 Associated Drug Sensitivity in Oral Carcinoma. Frontiers in oncology 22 32083004
2017 Zbtb7a induction in alveolar macrophages is implicated in anti-HLA-mediated lung allograft rejection. Science translational medicine 22 28701473
2014 FBI-1 enhances ETS-1 signaling activity and promotes proliferation of human colorectal carcinoma cells. PloS one 22 24857950
2016 Pokemon promotes the invasiveness of hepatocellular carcinoma by enhancing MEF2D transcription. Hepatology international 21 26797719
2010 P-Glycoprotein/MDR1 regulates pokemon gene transcription through p53 expression in human breast cancer cells. International journal of molecular sciences 21 20957096
2005 Pokemon expression in malignant glioma: an application of bioinformatics methods. Neurosurgical focus 21 16241110
2017 miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma. Oncotarget 20 28881782
2015 FBI-1 Is Overexpressed in Gestational Trophoblastic Disease and Promotes Tumor Growth and Cell Aggressiveness of Choriocarcinoma via PI3K/Akt Signaling. The American journal of pathology 20 26093985
2014 Pokemon enhances proliferation, cell cycle progression and anti-apoptosis activity of colorectal cancer independently of p14ARF-MDM2-p53 pathway. Medical oncology (Northwood, London, England) 20 25367850
2011 Epidermal growth factor increases LRF/Pokemon expression in human prostate cancer cells. Experimental and molecular pathology 19 21640721
2018 MiR-106b regulates the apoptosis and tumorigenesis of hepatocellular carcinoma via targeting Zinc finger and BTB domain-containing protein 7A (Zbtb7a). Journal of biochemical and molecular toxicology 18 29975452
2018 ZBTB7 evokes 5-fluorouracil resistance in colorectal cancer through the NF‑κB signaling pathway. International journal of oncology 18 30106136
2016 MicroRNA-137 represses FBI-1 to inhibit proliferation and in vitro invasion and migration of hepatocellular carcinoma cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 18 27492460
2012 Pokemon silencing leads to Bim-mediated anoikis of human hepatoma cell QGY7703. International journal of molecular sciences 18 22754333
2011 Expression of leukemia/lymphoma related factor (LRF/Pokemon) in human benign prostate hyperplasia and prostate cancer. Experimental and molecular pathology 18 21251909
2020 ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells. Oncogene 17 32115572
2020 Long Non-Coding RNA SNHG14 Impedes Viability, Migration and Invasion of Endometrial Carcinoma Cells Through Modulating miR-93-5p/ZBTB7A Axis. Cancer management and research 17 33061638
2018 The Praise and Price of Pokémon GO: A Qualitative Study of Children's and Parents' Experiences. JMIR serious games 17 29298750
2018 ZBTB7A governs estrogen receptor alpha expression in breast cancer. Journal of molecular cell biology 17 30265334
2020 Circular RNA Circ_0016760 Modulates Non-Small-Cell Lung Cancer Growth Through the miR-577/ZBTB7A Axis. Cancer management and research 15 32753969
2009 Eukaryotic translation initiator protein 1A isoform, CCS-3, enhances the transcriptional repression of p21CIP1 by proto-oncogene FBI-1 (Pokemon/ZBTB7A). Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 15 19471103
2023 ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5. Experimental & molecular medicine 14 36596853
2021 Knockdown of FBI-1 Inhibits the Warburg Effect and Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents via miR-3692/HIF-1α. Frontiers in oncology 14 34869045
2019 Knockdown of ZBTB7A inhibits cell proliferation of breast cancer through regulating the ubiquitination of estrogen receptor alpha. Life sciences 14 31715186
2018 ZBTB7/miR-137 Autoregulatory Circuit Promotes the Progression of Renal Carcinoma. Oncology research 14 29673422
2017 Upregulation of ZBTB7A exhibits a tumor suppressive role in gastric cancer cells. Molecular medicine reports 14 29207095
2015 Resveratrol Represses Pokemon Expression in Human Glioma Cells. Molecular neurobiology 14 25875864
2008 Expression of transcription factor Pokemon in non-small cell lung cancer and its clinical significance. Chinese medical journal 14 18364119
2023 U3 snoRNA-mediated degradation of ZBTB7A regulates aerobic glycolysis in isocitrate dehydrogenase 1 wild-type glioblastoma cells. CNS neuroscience & therapeutics 13 37066523
2022 ZBTB7A promotes virus-host homeostasis during human coronavirus 229E infection. Cell reports 13 36243002
2020 Obesity-Induced Upregulation of ZBTB7A Promotes Lipid Accumulation through SREBP1. BioMed research international 13 31998789
2014 Evaluation of transforming growth factor-β1 suppress Pokemon/epithelial-mesenchymal transition expression in human bladder cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 13 25722217
2013 Expression of the proto-oncogene Pokemon in colorectal cancer--inhibitory effects of an siRNA. Asian Pacific journal of cancer prevention : APJCP 13 24175766
2022 ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression. Cancer cell international 12 35501800
2021 Krüppel-like factor 1 (KLF1) promoted the proliferation, migration and invasion of human lens epithelial cells by enhancing the expression of Zinc Finger and BTB Domain Containing 7A (ZBTB7A) and activating Wnt/β-catenin pathway. Bioengineered 12 34304709
2020 Elevated ZBTB7A expression in the tumor invasive front correlates with more tumor budding formation in gastric adenocarcinoma. Journal of cancer research and clinical oncology 12 32965543
2019 Pokemon Inhibits Transforming Growth Factor β-Smad4-Related Cell Proliferation Arrest in Breast Cancer through Specificity Protein 1. Journal of breast cancer 12 30941230
2019 Pro-oncogene Pokemon Promotes Prostate Cancer Progression by Inducing STRN4 Expression. Journal of Cancer 12 31205540
2011 Pokemon reduces Bcl-2 expression through NF-κ Bp65: A possible mechanism of hepatocellular carcinoma. Asian Pacific journal of tropical medicine 12 21771706
2014 The effect of Pokemon on bladder cancer epithelial-mesenchymal transition. Biochemical and biophysical research communications 11 24393848

Missed literature

Know a paper Affinage missed for ZBTB7A? Flag it for the maintainers and the community.

No submissions yet.